Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Stomach Neoplasms 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Multiple Myeloma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 8Capecitabine 6pembrolizumab 5Carboplatin 5Pemetrexed 3Paclitaxel 3Oxaliplatin 3Irinotecan 3regorafenib 2osimertinib 2Taxes 2Sunitinib 2Radiotherapy 2Fluorouracil 2Cisplatin 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tislelizumab 1tegafur-gimeracil-oteracil 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1sintilimab 1seribantumab 1selinexor 1ruxolitinib 1rubitecan 1pralsetinib 1palbociclib 1olaparib 1niraparib 1linifanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma × dostarlimab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡